Consolidated Balance Sheets - USD ($)
|
Feb. 28, 2023 |
Nov. 30, 2022 |
| Current Assets |
|
|
| Cash and cash equivalents |
$ 1,373,099
|
$ 1,703,958
|
| Marketable securities |
840,277
|
17,620
|
| Accounts receivable (net of allowance for doubtful accounts of $3,580,233 and $3,528,119, respectively) |
6,522,456
|
6,043,941
|
| Prepaid expenses |
580,144
|
566,557
|
| Inventory, current portion |
900,052
|
851,230
|
| Other current assets |
421,083
|
426,879
|
| Total current assets |
10,637,111
|
9,610,185
|
| Property and Equipment-net |
14,426,725
|
13,603,115
|
| Other Assets |
|
|
| Duke license agreement |
13,450,834
|
13,691,028
|
| Intangible assets, net |
1,439,217
|
1,463,312
|
| Inventory, net of current portion |
8,996,063
|
9,275,344
|
| Goodwill |
1,941,411
|
1,941,411
|
| Deferred tax assets |
13,742,399
|
13,742,399
|
| Operating lease right-of-use asset |
526,710
|
606,034
|
| Deposits and other assets, net |
665,565
|
647,226
|
| Total other assets |
41,070,199
|
41,674,754
|
| Total assets |
66,134,035
|
64,888,054
|
| Current Liabilities |
|
|
| Accounts payable |
2,363,757
|
1,605,301
|
| Accrued expenses |
3,074,903
|
3,585,810
|
| Note payable |
158,456
|
150,527
|
| Line of credit |
1,772,728
|
2,272,728
|
| Current portion of operating lease liability |
288,902
|
297,691
|
| Current portion of Duke license agreement liability |
2,000,000
|
1,983,036
|
| Deferred revenue |
9,253,131
|
9,586,327
|
| Total current liabilities |
18,911,877
|
19,481,420
|
| Other Liabilities |
|
|
| Deferred revenue, net of current portion |
37,246,889
|
36,000,059
|
| Contingent consideration |
998,003
|
1,162,704
|
| Note payable, net of current portion and debt issuance costs |
8,547,744
|
8,579,875
|
| Operating lease long-term liability |
242,039
|
313,298
|
| Long-term liability - revenue sharing agreements |
875,000
|
875,000
|
| Total other liabilities |
47,909,675
|
46,930,936
|
| Total liabilities |
66,821,552
|
66,412,356
|
| Commitments and contingencies (Note 9) |
0
|
0
|
| Stockholders' Deficit |
|
|
| Preferred stock |
0
|
0
|
| Common stock ($.01 par value, 20,000,000 authorized; 14,848,001 issued and 8,443,230 outstanding as of February 28, 2023 and 14,848,001 issued and 8,500,511 outstanding as of November 30, 2022) |
148,480
|
148,480
|
| Additional paid-in capital |
42,910,554
|
42,597,380
|
| Treasury stock, at cost |
(22,875,850)
|
(22,632,649)
|
| Accumulated deficit |
(20,870,701)
|
(21,637,513)
|
| Total stockholders' deficit |
(687,517)
|
(1,524,302)
|
| Total liabilities and stockholders' equity |
66,134,035
|
64,888,054
|
| Series A Junior Participating Preferred Stock [Member] |
|
|
| Stockholders' Deficit |
|
|
| Preferred stock |
0
|
0
|
| Tianhe Stem Cell Biotechnologies Inc [Member] |
|
|
| Other Assets |
|
|
| Investment |
$ 308,000
|
$ 308,000
|